ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App
Shots: The P-III trial involves assesing of Sarclisa (IV, 10mg/kg qw for four weeks) in combination with carfilzomib (20/56mg/m2, bid) and dexamethasone in 302 patients with relapsed multiple myeloma across 69 centers spanning 16 countries The study resulted in meeting its 1EP and resulted in the reduction of risk of disease progression or death with […]Read More
